BER Stock Overview
Bioerg Spólka Akcyjna focuses on trading of food and chemical products in Poland.
Bioerg Spólka Akcyjna Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł0.17|
|52 Week High||zł0.31|
|52 Week Low||zł0.10|
|1 Month Change||-6.61%|
|3 Month Change||19.37%|
|1 Year Change||-41.55%|
|3 Year Change||69.50%|
|5 Year Change||54.09%|
|Change since IPO||-75.79%|
Recent News & Updates
|BER||PL Biotechs||PL Market|
Return vs Industry: BER underperformed the Polish Biotechs industry which returned -40% over the past year.
Return vs Market: BER underperformed the Polish Market which returned -15.6% over the past year.
|BER Average Weekly Movement||17.7%|
|Biotechs Industry Average Movement||7.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in PL Market||13.4%|
|10% least volatile stocks in PL Market||4.5%|
Stable Share Price: BER is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: BER's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Bioerg Spólka Akcyjna focuses on trading of food and chemical products in Poland. It engages in the wholesale and retail trade of ecological food products for humans and animals; and household chemical products. The company also undertakes technical maintenance of industrial installations; repairs installations, equipment, and industrial fittings; repairs and services machines; implements tasks related to prefabrication; and provides technical consultancy, cleaning, and machining services.
Bioerg Spólka Akcyjna Fundamentals Summary
|BER fundamental statistics|
Is BER overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BER income statement (TTM)|
|Cost of Revenue||zł1.08m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Aug 10, 2022
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-250.37%|
How did BER perform over the long term?See historical performance and comparison
Is Bioerg Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BER is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.
PE vs Market: BER is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BER's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BER is overvalued based on its PB Ratio (38.3x) compared to the PL Biotechs industry average (4.5x).
How is Bioerg Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioerg Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bioerg Spólka Akcyjna performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BER is currently unprofitable.
Growing Profit Margin: BER is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BER is unprofitable, and losses have increased over the past 5 years at a rate of 82.6% per year.
Accelerating Growth: Unable to compare BER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BER is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: BER has a negative Return on Equity (-2819.17%), as it is currently unprofitable.
How is Bioerg Spólka Akcyjna's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BER's short term assets (PLN1.1M) exceed its short term liabilities (PLN962.5K).
Long Term Liabilities: BER's short term assets (PLN1.1M) exceed its long term liabilities (PLN2.5K).
Debt to Equity History and Analysis
Debt Level: BER has more cash than its total debt.
Reducing Debt: BER's debt to equity ratio has increased from 0.02% to 79.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BER has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BER has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33% each year
What is Bioerg Spólka Akcyjna current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BER's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BER's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BER's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BER's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BER has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Piotr Klomfas serves as Chairman of Management Board at Bioerg Spólka Akcyjna since September 2020.
Experienced Board: BER's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioerg Spólka Akcyjna's employee growth, exchange listings and data sources
- Name: Bioerg Spólka Akcyjna
- Ticker: BER
- Exchange: WSE
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł17.236m
- Shares outstanding: 101.68m
- Website: https://www.bioerg.pl
Number of Employees
- Bioerg Spólka Akcyjna
- ul. Chemików 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.